Skip to main content
SpringerLink
Log in

Pharmacological Targets of Hypertension

  • Chapter
  • First Online:
Heart of the Matter

Part of the book series: Learning Materials in Biosciences ((LMB))

  • 1039 Accesses

Abstract

This chapter will begin by briefly explaining the parameters that form blood pressure, in addition to the cardiovascular burden of hypertension (HTN). From there, the key physiological modulators of blood pressure, namely autonomic tone, humoral factors, local and cellular factors, will be discussed, as will the renin–angiotensin–aldosterone system. Pharmacological agents used in the treatment of HTN will then be expanded upon, with the scientific rationale for each explored. Finally, we will explore two classes of drug that present new opportunities for the therapeutic modulation of blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al (2018) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary. Hypertension. 71(6): 1269–1324

    Google Scholar 

  2. Carretero OA, Oparil S (2000) Essential hypertension. Part I: definition and etiology. Circulation 101:329

    Article  CAS  PubMed  Google Scholar 

  3. Gaciong Z, Siński M, Lewandowski J (2013) Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep 15:559

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Collins R et al (1990) Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335:827

    Article  CAS  PubMed  Google Scholar 

  5. Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S et al (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527

    Article  CAS  PubMed  Google Scholar 

  6. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957

    Article  PubMed  Google Scholar 

  7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206

    Article  CAS  PubMed  Google Scholar 

  8. Shah S, Khatri I, Freis ED (1978) Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 95:611

    Article  CAS  PubMed  Google Scholar 

  9. Hropot M, Fowler N, Karlmark B, Giebisch G (1985) Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int 28:477

    Article  CAS  PubMed  Google Scholar 

  10. Liang W, Ma H, Cao L, Yan W, Yang J (2017) Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med 21:2634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Salvetti A (2006) Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 17:S25

    Article  CAS  PubMed  Google Scholar 

  12. Wittner M, Di Stefano A, Wangemann P, Greger R (1991) How do loop diuretics act? Drugs 41:1

    Article  CAS  PubMed  Google Scholar 

  13. Tamargo J, Segura J, Ruilope LM (2014) Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 15:605

    Article  CAS  PubMed  Google Scholar 

  14. Wile D (2012) Diuretics: a review. Ann Clin Biochem 49:419

    Article  CAS  PubMed  Google Scholar 

  15. Peti-Peterdi J, Harris RC (2010) Macula Densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 21:1093

    Article  CAS  PubMed  Google Scholar 

  16. Kawai T, Forrester SJ, O’Brien S, Baggett A, Rizzo V, Eguchi S (2017) AT1 receptor signaling pathways in the cardiovascular system. Pharmacol Res 125:4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Soundararajan R, Pearce D, Ziera T (2012) The role of the ENaC-regulatory complex in aldosterone-mediated sodium transport. Mol Cell Endocrinol 350:242

    Article  CAS  PubMed  Google Scholar 

  18. Weber MA (2005) The role of the new β-blockers in treating cardiovascular disease. Am J Hypertens 18:169

    Article  CAS  Google Scholar 

  19. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013) Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168:3572

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342:905

    Article  CAS  PubMed  Google Scholar 

  21. Morales DR, Guthrie B, Lipworth BJ, Donnan PT, Jackson C (2011) Prescribing of β-adrenoceptor antagonists in asthma: an observational study. Thorax 66:502

    Article  PubMed  Google Scholar 

  22. MĂĽller DN, Luft FC (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol: CJASN 1:221

    Article  CAS  PubMed  Google Scholar 

  23. Gao D, Ning N, Niu X, Wei J, Sun P, Hao G (2011) Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am J Hypertens 24:613

    Article  CAS  PubMed  Google Scholar 

  24. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF (2018) Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol 71:1474

    Article  CAS  PubMed  Google Scholar 

  25. MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82:57

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sica DA (2004) Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations. J Clin Hypertens (Greenwich) 6:410

    Article  CAS  Google Scholar 

  27. Taylor AA, Siragy H, Nesbitt S (2011) Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens 13:677

    Article  CAS  Google Scholar 

  28. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M et al (2007) Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25:951

    Article  CAS  PubMed  Google Scholar 

  29. Munger MA (2011) Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T 36:22

    PubMed  PubMed Central  Google Scholar 

  30. Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC (2004) Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br Med J 329:828

    Article  CAS  Google Scholar 

  31. Strauss MH, Hall AS (2006) Angiotensin receptor blockers may increase risk of myocardial infarction unraveling the ARB-MI paradox. Circulation 114:838

    Article  PubMed  Google Scholar 

  32. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24:486

    Article  CAS  PubMed  Google Scholar 

  33. Investigators TO (2008 [cited 2019 Jan 3]) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med [Internet] 358(15):1547–59. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0801317

  34. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893

    Article  CAS  PubMed  Google Scholar 

  35. Guichard JL, Clark D, Calhoun DA, Ahmed MI (2013) Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 9:321–31

    Google Scholar 

  36. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709

    Article  CAS  PubMed  Google Scholar 

  37. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839

    Article  CAS  PubMed  Google Scholar 

  38. Brown NJ (2003) Eplerenone: cardiovascular protection. Circulation 107:2512

    Article  CAS  PubMed  Google Scholar 

  39. Muntwyler J, Follath F (2001) Calcium channel blockers in treatment of hypertension. Prog Cardiovasc Dis 44(3):207–216

    Article  CAS  PubMed  Google Scholar 

  40. Opie LH (1997) Pharmacological differences between calcium antagonists. Eur Heart J 18:71

    Article  Google Scholar 

  41. Hedner T (1986) Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol (Copenh) 58(Suppl 2):119–130

    CAS  Google Scholar 

  42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981. https://jamanetwork.com/journals/jama/fullarticle/195626

  43. Carruthers SG (1994) Adverse effects of α1-adrenergic blocking drugs. Drug Saf 11:12

    Article  CAS  PubMed  Google Scholar 

  44. Sica DA (2007) Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 9:399

    Article  CAS  Google Scholar 

  45. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K (2015) Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J 36:1967

    Article  CAS  PubMed  Google Scholar 

  46. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL et al (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106:920

    Article  CAS  PubMed  Google Scholar 

  47. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17:103

    Article  CAS  PubMed  Google Scholar 

  48. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993

    Article  CAS  PubMed  Google Scholar 

  49. Schiffrin EL (2005) Vascular endothelin in hypertension. Vasc Pharmacol 43:19

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imperial College London, London, UK

    Haaris Rahim & Yasmin Bashir

  2. National Heart and Lung Institute, Myocardial Function, Imperial College London, London, UK

    Michael Schachter

Authors
  1. Haaris Rahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasmin Bashir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Schachter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Schachter .

Editor information

Editors and Affiliations

  1. National Heart & Lung Institute, Imperial College London, London, UK

    Cesare Terracciano

  2. Imperial College London & St George’s Medical School, London, UK

    Samuel Guymer

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rahim, H., Bashir, Y., Schachter, M. (2019). Pharmacological Targets of Hypertension. In: Terracciano, C., Guymer, S. (eds) Heart of the Matter. Learning Materials in Biosciences. Springer, Cham. https://doi.org/10.1007/978-3-030-24219-0_15

Download citation

Publish with us

Policies and ethics

Search

Navigation